ABCG2 and hyperuricemia: Since allopurinol, febuxostat, topiroxostat and benzbromarone are the major SUA-lowering drugs presently known, the development of SUA-lowering drugs that do not inhibit ABCG2 would be the next strategy for developing a more effective hyperuricemia therapy.